{
    "persona": "conservative",
    "model": "mixtral:8x7b-instruct-v0.1-q6_K",
    "topic": "healthcare",
    "language": "English",
    "text": "Long-term data on atogepant for migraine prevention shows promising efficacy and safety over 48 weeks, with an average reduction of 8.5 monthly migraine days. A positive step for patients seeking long-lasting relief!",
    "retrieved_source": "https://www.medscape.com/viewarticle/first-long-term-data-atogepant-migraine-prevention-2024a10007cb",
    "annotation": {
        "topic": null,
        "persona": null,
        "authenticity": null
    },
    "id": "17f4e68249ad3f44242d5a470fce83b755eb52b9b593670c"
}